Navigation Links
HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find

Interleukin-2 (IL-2), an immune-boosting drug used experimentally in HIV therapy, greatly increases the lifespan of certain subsets of immune system T cells in some HIV-positive people who respond to this therapy, discovered researchers from the National Institutes of Health (NIH) Clinical Center and the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. A report describing the study, led by the Clinical Center’s Joseph A. Kovacs, M.D., appears online today in The Journal of Clinical Investigation.

A hallmark of HIV infection is the progressive loss of CD4+ T cells (a key type of white blood cell) and the subsequent decline in the infected person’s ability to fend off disease. NIH clinical investigators pioneered the experimental use of IL-2 in HIV therapy to help boost the immune systems of people with HIV infection. Produced naturally by T cells, IL-2 is a powerful immune system regulator. While its use in HIV therapy is experimental and can be associated with various side effects, IL-2 is licensed to treat certain cancers.

NIH researchers have long observed that in responsive patients, intermittent cycles of IL-2 therapy lead to substantial increases in the number of circulating CD4+ cells. The mechanisms driving this increase as well as its potential clinical significance, however, have remained unclear, note the scientists.

Using two relatively new techniques for labeling cells, the team demonstrated that IL-2 therapy can lead to greatly increased numbers of new CD4+ cells. “More remarkable than the proliferation of these cells was how long they lived,?says Dr. Kovacs. The average lifespan of CD4+ cells in healthy individuals as measured with this technique is about four weeks, according to Dr. Kovacs. In contrast, the average lifespan of CD4+ cells in 15 HIV-positive volunteers who had received three or more courses of IL-2 was 37.6 weeks, about nine times longer.

In the first set of experiments, inve stigators infused 32 volunteers with a sugar solution containing a harmless chemical label, deuterium (a non-radioactive, stable isotope), for five days. Nine volunteers were HIV-positive but had never received IL-2; 15 volunteers were HIV-positive and had received between three and 28 courses of IL-2; and eight volunteers were HIV-negative.

Deuterium is incorporated into the DNA of actively dividing cells. By taking blood samples in weeks and months following the deuterium infusion and measuring the amount of deuterium remaining in the CD4+ T cell DNA at each time point, the researchers could count how many new cells were made and how long they lived.

The scientists found a marked increase in the numbers of newly made CD4+ cells in all the HIV-positive, IL-2 responsive volunteers. In two HIV-positive volunteers ?each of whom had received multiple five-day courses of IL-2 over several years ?the researchers detected CD4+ cells that lived for about three years, a result Dr. Kovacs calls “quite surprising.?/p>

Using another labeling technique, the researchers determined that IL-2 boosts the numbers of two subsets of CD4+ cells: naïve cells, those that have never encountered an infectious agent; and central memory cells, those that have encountered an infectious agent before and are primed to respond quickly if they encounter the same agent again.

The new data complement clinical observations suggesting that IL-2’s effects on HIV disease progression may become apparent only in long-term follow-up, says Dr. Kovacs. Two large, long-term efficacy trials currently underway should provide a clearer picture of the clinical impact of IL-2 on the course of HIV disease and its potential role in the management of HIV-infected patients, he adds. Information on these and other HIV clinical trials is available at www.aidsinfo.nih.gov.

Other authors on the paper include researchers from the NIH’s National Cancer Institute and the Science Applicati ons International Corporation of Frederick, MD.


'"/>

Source:NIH


Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
3. Gene Therapy For Parkinsons Disease Moves Forward In Animals
4. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
5. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
6. Discovery Promises Simpler Therapy for Sickle Cell Disease
7. Gene Therapy Cures Inherited Liver Disease In Rats
8. Antiretroviral Therapy May Prevent HIV Transmission From Breastfeeding Mothers To Infants
9. Menopause Symptoms May Come Back After Stopping Menopausal Hormone Therapy
10. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
11. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology: